Paper · 42563409
Ocular Tissue Distribution of Ocular Surface Immunoglobulin Following Topical and Subconjunctival Administration: A Novel Strategy for Mitigation of Antibody-Drug Conjugate-Associated Ocular Toxicity.
Dabre Z and 10 others. J Ocul Pharmacol Ther, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Ocular Tissue Distribution of Ocular Surface Immunoglobulin Following Topical and Subconjunctival Administration: A Novel Strategy for Mitigation of Antibody-Drug Conjugate-Associated Ocular Toxicity. Papers, record 42563409. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42563409
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ocular Tissue Distribution of Ocular Surface Immunoglobulin Following Topical and Subconjunctival Administration: A Novel Strategy for Mitigation of Antibody-Drug Conjugate-Associated Ocular Toxicity.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| I01 BX007265 | BLRD VA | United States | I01BX007265 | PubMed | NIH RePORTER |
| P30 EY001792 | NEI NIH HHS | United States | P30EY001792 | PubMed | NIH RePORTER |
| R24 EY032440 | NEI NIH HHS | United States | R24EY032440 | PubMed | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41,162,290 | Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2026 | https://conductscience.org/library/papers/41162290 | PubMed |
| 2 | 24,242,219 | The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model. | Eur J Ophthalmol | 2014 | https://conductscience.org/library/papers/24242219 | PubMed |
| 3 | 38,366,236 | Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy. | Pharm Res | 2024 | https://conductscience.org/library/papers/38366236 | PubMed |
| 4 | 42,134,305 | Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges. | Cell | 2026 | https://conductscience.org/library/papers/42134305 | PubMed |
| 5 | 31,028,836 | Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. | Pharmacol Ther | 2019 | https://conductscience.org/library/papers/31028836 | PubMed |
| 6 | 36,765,668 | Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36765668 | PubMed |
| 7 | 38,959,480 | Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. | N Engl J Med | 2024 | https://conductscience.org/library/papers/38959480 | PubMed |
| 8 | 36,408,673 | Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. | Cancer | 2023 | https://conductscience.org/library/papers/36408673 | PubMed |
| 9 | 28,655,784 | Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia. | Mol Cancer Ther | 2017 | https://conductscience.org/library/papers/28655784 | PubMed |
| 10 | 29,382,707 | Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates. | Cancer Res | 2018 | https://conductscience.org/library/papers/29382707 | PubMed |
1 to 10 of 40
See all 40 referencesCited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42,792,744 | MSC EVs Deliver miRNAs into Cardiomyocytes via EIPA-Sensitive and Clathrin-Mediated Endocytosis. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792744 |
Source PubMed
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42563409
GET https://conductscience.org/api/papers/v1/42563409/references?page=2